Why AI matters at this scale

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of novel therapies for chronic and life-threatening conditions, primarily in pulmonary arterial hypertension and other orphan diseases. With a portfolio spanning small molecules, biologics, and innovative organ manufacturing technologies, its mission centers on addressing high-unmet medical needs. At a mid-market size of 501-1000 employees, the company operates at a critical inflection point: large enough to generate significant proprietary R&D and clinical data, yet agile enough to integrate new technologies without the inertia of a pharmaceutical giant. In the high-stakes, capital-intensive world of drug development, AI is not merely an efficiency tool but a fundamental lever for survival and growth. It enables a company of this scale to compete with larger peers by accelerating discovery, de-risking clinical investments, and personalizing therapeutic approaches.

Concrete AI Opportunities and ROI

1. Accelerating Target Discovery and Validation: The most transformative opportunity lies in applying machine learning to multi-omics data (genomics, proteomics) from pulmonary patients. AI models can identify novel drug targets and predictive biomarkers far faster than traditional methods. For a company focused on rare diseases with small patient populations, this precision is invaluable. The ROI is measured in years saved in the preclinical pipeline and increased probability of technical success, directly impacting the valuation of the R&D portfolio.

2. Optimizing Clinical Trial Execution: Clinical trials represent the single largest cost center. Natural Language Processing (NLP) can mine electronic health records and scientific literature to optimize trial design and identify ideal investigator sites. More impactful is using AI for patient stratification, ensuring the right patients are enrolled based on predicted treatment response. This reduces trial size, duration, and cost while increasing the likelihood of demonstrating statistical significance—a direct financial return measured in tens of millions of dollars per trial.

3. Enhancing Manufacturing and Supply Chain: For biologic therapies and potentially manufactured organs, AI-driven process analytical technology (PAT) can monitor and control complex manufacturing in real-time. Predictive maintenance on critical equipment and AI for quality control can drastically reduce batch failures and improve yield. The ROI here is in reduced cost of goods sold (COGS) and more reliable supply, protecting revenue streams from high-margin products.

Deployment Risks for a Mid-Sized Biotech

Deploying AI at this size band carries distinct risks. First is talent acquisition: competing with tech giants and larger pharma for scarce AI/ML talent strains resources, making strategic partnerships or focused niche hiring essential. Second is data infrastructure: existing data is often siloed across research, clinical, and commercial functions. Building a unified, quality-controlled data lake requires significant upfront investment and cross-departmental cooperation, which can be challenging without top-down mandate. Third is regulatory risk: using AI in drug discovery or clinical decision support introduces novel regulatory questions. The FDA's evolving framework for AI/ML as a medical device or as part of drug development creates uncertainty. A misstep in validation or documentation could delay projects or lead to costly rework. Finally, there's pilot purgatory: the company has resources for pilots but may lack the scale to productionize successful models across the enterprise, leading to isolated wins that fail to transform core operations. A clear roadmap from pilot to integration is critical.